Table 1 Previous reports of combined therapy with peritoneal dialysis and hemodialysis
First author, year [Ref.] | Country | Study design | Number | Duration of PD at start of combined therapy (years) | Follow-up period (months) | Main outcome |
|---|---|---|---|---|---|---|
Kawanishi, 1999 [27] | Japan | Single-center retrospective | 12 | 4.1 ± 3.6 | 3 | Increased Kt/V |
Hashimoto, 2000 [28] | Japan | Single-center retrospective | 6 | 2.1 ± 0.9 | 3 | Quality of life, medical costs |
Kawanishi, 2002 [3] | Japan | Single-center retrospective | 31 (12) | (99.4 ± 30.1) | (25.2 ± 18.8) | Dialysis dose and body fluid |
Kanno, 2003 [29] | Japan | Single-center retrospective | 7 | 4.3 ± 1.1 | 6 | Solute clearance and symptoms |
Agarwal, 2003 [30] | USA | Multicenter retrospective | 31 | 4.3 ± 4.1 | 6 | Solute clearance and symptoms |
McIntyre, 2004 [31] | UK | Prospective | 8 | 0 at initiation | 12 | Blood pressure, left ventricular mass index reduced |
Kawanishi, 2006 [32] | Japan | Multicenter retrospective | 52 | 3.6 ± 3.0 | 24 | Adequate solute, fluid removal without PD alone |
Hoshi, 2006 [33] | Japan | Single-center retrospective | 9 | 3.6 ± 0.2 | 36 | Clinical status for whom adequate solute |
Kawanishi, 2007[5] | Japan | Multicenter (four center) retrospective | 52 | 3.6 ± 3.0 | 6 | Prolonged PD duration |
Matsuo, 2010 [6] | Japan | Single-center retrospective | 53 | 4.1 ± 3.2 | 12 | Controlled overhydration and corrected solute removal |
Moriishi, 2010 [8] | Japan | Single-center retrospective | 76 | 4.1(mean) | N/A | Retention of peritoneal function |
Tanaka, 2011 [34] | Japan | Single-center retrospective | 14 | 3.8 (mean) | 9 | Left ventricular mass index |
Suzuki, 2012 [14] | Japan | Single-center retrospective | 10 | Within 1 year | 72 (Max) | Early start of PDHD prolonged the duration of PD |
Maruyama, 2014 [7] | Japan | Multicenter retrospective | 104 | 4.0 ± 3.5 | 3 | Improve overhydration and inadequate dialysis |
Kanda, 2017 [10] | Japan | Single-center prospective | 30 | 3.2 ± 1.8 | 18 | D/PCr in long-term, left ventricular mass index |
Ueda, 2017 [35] | Japan | Single-center retrospective | 13 | 0 at initiation | 30 | Preserving both RRF and serum albumin |
Banshodani, 2019 [36] | Japan | Single-center retrospective | 93 LEF (n = 29) NEF(n = 64) | LEF:3.6 ± 3.3 NEF:4.5 ± 3.2 | 36 | Hospitalization rate for acute cardiovascular events |
Abe, 2019 [37] | Japan | Multicenter prospective | 1679 | N/A | 24 | Mortality and cardiovascular events |
Tanaka, 2020 [12] | Japan | Multicenter prospective | 46 | 5.8 ± 3.1 | 46 | Dialysis access–related complications |
Chung, 2020 [21] | Taiwan | Multicenter retrospective | 688 | 2.5 ± 2.1 | 2.1 ± 2.0 | Cost-effective |
Maruyama, 2021 [11] | Japan | Multicenter prospective | 47 | 2.4 (1.4–3.6) | 41 (mean) | Survival |
Murashima, 2021 [22] | Japan | Multicenter retrospective | 608 | 2.1 (1.0–4.1) | 30 (median) | Mortality |
Maruyama, 2021 [38] | Japan | Multicenter retrospective | 26 | 4.9 | N/A | Fatigue measured by the POMS, VAS |
Kawanishi, 2021 [39] | Japan | Multicenter prospective | 79 | N/A | 20 (median) | Mortality, hospitalization |
Ueda, 2021 [40] | Japan | Single-center retrospective | 4 | 0 at initiation | 24 (mean) | Peritoneal permeability after the short-term peritoneal rest |